Inhibikase Therapeutics, Inc. IKT
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -24.88%
- 1 year
- +4.76%
- Open
- 1.56
- Prev close
- 1.55
- Mkt cap
- 214.89M
- Vol
- 449.23K
- Avg vol
- 575.16K
- EPS
- -0.43
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.47
- High
- 1.59
- Forward P/E
- -11.84
- Beta
- 1.12
- Short ratio
- 0.17
- Inst. own
- 11.62%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 2.62
- 200-d avg
- 1.84
- 1y target
- 7.00
5D chart
Signals (47)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 10:15 AM | 8 hours ago |
| SMA: Bearish | Nov 2, 9:40 AM | 8 hours ago |
| SMA: Bearish | Nov 2, 9:40 AM | 8 hours ago |
| SMA: Bullish | Nov 2, 9:30 AM | 9 hours ago |
| SMA: Bullish | Nov 2, 9:30 AM | 9 hours ago |
| MACD: Buy Signal | Oct 30, 3:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:20 PM | 3 days ago |
| RSI: Oversold | Oct 30, 2:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:00 PM | 3 days ago |
| RSI: Oversold | Oct 30, 12:45 PM | 3 days ago |
| RSI: Oversold | Oct 30, 12:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:35 AM | 3 days ago |
| RSI: Oversold | Oct 30, 11:35 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 3:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:10 PM | 4 days ago |
| RSI: Oversold | Oct 29, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:40 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 3:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 2:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 12:20 PM | 5 days ago |
| RSI: Overbought | Oct 28, 11:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 10:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:10 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:30 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:40 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 2:35 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 1:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 1:40 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 12:35 PM | 6 days ago |
| RSI: Overbought | Oct 27, 12:05 PM | 6 days ago |
News
6 days ago globenewswire.com
Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
WILMINGTON, Del., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel…
1 week ago globenewswire.com
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel…
-
2 weeks ago benzinga.com
Chardan Capital Initiates Coverage On Inhibikase Therapeutics with Neutral Rating, Announces Price Target of $1.5
Chardan Capital analyst Andreas Argyrides initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Neutral rating and announces Price Target of $1.5.
1 month ago globenewswire.com
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to…
1 month ago defenseworld.net
Critical Survey: Inhibikase Therapeutics (NASDAQ:IKT) and Otsuka (OTCMKTS:OTSKY)
Otsuka (OTCMKTS:OTSKY - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two…
1 month ago defenseworld.net
Financial Review: Inhibikase Therapeutics (NASDAQ:IKT) vs. Eli Lilly and Company (NYSE:LLY)
Eli Lilly and Company (NYSE: LLY - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the…
-
2 months ago benzinga.com
Inhibikase Therapeutics Q2 EPS $(0.11), Inline
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
2 months ago globenewswire.com
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel…
3 months ago defenseworld.net
ADAR1 Capital Management LLC Reduces Stock Position in Inhibikase Therapeutics, Inc. $IKT
ADAR1 Capital Management LLC reduced its stake in Inhibikase Therapeutics, Inc. (NASDAQ: IKT) by 18.1% in the first quarter, according to its most recent Form 13F filing with the Securities and…
-
3 months ago benzinga.com
Inhibikase Therapeutics Says FDA Grants Orphan Drug Designation To Its Lead Product Candidate IKT-001, Prodrug Of Imatinib Mesylate, For Treatment Of PAH
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), today announced
3 months ago globenewswire.com
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
WILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary…
3 months ago benzinga.com
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading. Other stocks also decline.
-
3 months ago benzinga.com
Inhibikase Therapeutics Sells 25M Common Shares To RA Capital Management Through At-The-Market Facility For Gross Proceeds Of $50M
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), today announced
3 months ago globenewswire.com
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary…
4 months ago globenewswire.com
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del., July 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to…
-
4 months ago benzinga.com
Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5
Oppenheimer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Outperform rating and announces Price Target of $5.
-
5 months ago benzinga.com
Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 33.33 percent increase over losses…
5 months ago globenewswire.com
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary…
-
6 months ago benzinga.com
Inhibikase Therapeutics Says First Patient Enrolled In Pivotal Phase 3 Study IMPROVE-PAH For Treatment Of Pulmonary Arterial Hypertension
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), announced today that…
6 months ago globenewswire.com
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary…
7 months ago globenewswire.com
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to…
-
7 months ago benzinga.com
Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 33.33 percent increase over losses…
7 months ago globenewswire.com
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify…
7 months ago defenseworld.net
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Up 52.2% in February
Inhibikase Therapeutics, Inc. (NASDAQ: IKT - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 27th, there was short interest…
-
8 months ago benzinga.com
Ladenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $4
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $4.
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
8 months ago defenseworld.net
Analyzing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP)
Inhibikase Therapeutics (NYSE: IKT - Get Free Report) and Big Cypress Acquisition (OTCMKTS:BCYP - Get Free Report) are both small-cap medical companies, but which is the superior business? We will…
8 months ago defenseworld.net
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of “Buy” from Analysts
Inhibikase Therapeutics, Inc. (NASDAQ: IKT - Get Free Report) has been given a consensus recommendation of "Buy" by the five research firms that are currently covering the stock, Marketbeat Ratings…
8 months ago defenseworld.net
Comparing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP)
Big Cypress Acquisition (OTCMKTS:BCYP - Get Free Report) and Inhibikase Therapeutics (NYSE: IKT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will…
-
9 months ago benzinga.com
B of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $6
B of A Securities analyst Jason Zemansky initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $6.
10 months ago defenseworld.net
Comparing Liminatus Pharma (NASDAQ:LIMN) & Inhibikase Therapeutics (NASDAQ:IKT)
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will…
10 months ago defenseworld.net
Liminatus Pharma (NASDAQ:LIMN) vs. Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Contrast
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will…
10 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
10 months ago benzinga.com
HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $8.
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
10 months ago benzinga.com
Inhibikase Therapeutics Files SEC Prospectus To Raise Up To $185M Through Existing ATM Program
On December 19, 2025, Inhibikase Therapeutics, Inc. (the "Company") filed with the Securities and Exchange Commission (the "SEC") a prospectus supplement (the "Prospectus Supplement"), dated December…
-
10 months ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4
Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Overweight rating and announces Price Target of $4.
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
11 months ago benzinga.com
Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
-
11 months ago benzinga.com
Inhibikase Therapeutics Announces Common Stock Offering; Terms Not Disclosed
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension…
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
11 months ago benzinga.com
Inhibikase Therapeutics Announces Plans To Advance Its PAH Therapeutic Candidate, IKT-001, Into A Global Phase 3 Trial And Is Expected To Begin In Q1 2026
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely,…
-
11 months ago benzinga.com
Inhibikase Therapeutics Q3 EPS $(0.13), Inline
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is a 80 percent increase over losses of $(0.65) per share from the…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
1 year ago benzinga.com
Inhibikase Therapeutics Q2 EPS $(0.11) Misses $(0.09) Estimate
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 83.33 percent increase over…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
Inhibikase Therapeutics Files For Mixed Shelf Of Up To $300M
https://www.sec.gov/Archives/edgar/data/1750149/000119312525143738/d77556ds3.htm